Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Tecan Group Ltd, commonly referred to as Tecan, is a leading global provider of laboratory instruments and solutions, headquartered in Switzerland (CH). Founded in 1980, Tecan has established itself as a key player in the life sciences and diagnostics industries, with a strong presence in Europe, North America, and Asia.
The company specialises in the development and manufacturing of automated laboratory systems, including liquid handling, microplate readers, and assay development tools. Tecan's innovative products are designed to enhance laboratory efficiency and accuracy, making them indispensable in research and clinical settings.
With a commitment to quality and innovation, Tecan has achieved significant milestones, including numerous awards for its cutting-edge technologies. The company is recognised for its strong market position, serving a diverse clientele that includes pharmaceutical, biotechnology, and academic institutions worldwide.
+68 vs industry average
Tecan’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
In 2025, Tecan Group Ltd. reported total greenhouse gas emissions of approximately 391.4 million kg CO2e. This includes 1,945,000 kg CO2e from Scope 1 emissions, 102,000 kg CO2e from Scope 2 emissions, and a significant 389,343,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2022 base year. Additionally, Tecan is committed to achieving net-zero emissions across all scopes by 2050, targeting a 90% reduction in absolute emissions from 2022 levels.
Tecan's near-term targets include increasing the sourcing of renewable electricity from 34% in 2022 to 100% by 2025, and maintaining this commitment through 2030. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Tecan's commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector. The company operates from its headquarters in Switzerland (CH) and is actively working towards reducing its carbon footprint in line with global climate goals.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 2
Tecan Group Ltd commits to reduce absolute scope 2 GHG emissions 42% by 2030 from a 2022 base year.
2030
42% reduction in Scope 1
Tecan Group Ltd commits to reduce absolute scope 1 GHG emissions 42% by 2030 from a 2022 base year.
2030
42% reduction in scope 3 total
Tecan Group Ltd commits to reduce absolute scope 3 GHG emissions 42% by 2030 from a 2022 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


Common questions about Tecan’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more